Metagenome-driven microbiome research is providing important new insights in fields as diverse as the pathogenesis of human disease, the metabolic interactions of complex microbial ecosystems involved in agriculture, and climate change. However, poor correlations typically observed between RNA and protein expression datasets even for single organisms make it hard to infer microbial protein expression with any accuracy from metagenomic data, thus restricting movement beyond microbial catalogues and into functional analysis of microbial effector molecules. By contrast, mass spectrometry analysis of microbiome data at the protein level in theory allows direct measurement of dynamic changes in microbial protein composition, localisation and modification that may mediate host/pathogen interactions in complex microbial ecosystems, but analysis of such metaproteomic datasets remains challenging.
Abstract
Metagenome-driven microbiome research is providing important new insights in fields as diverse as the pathogenesis of human disease, the metabolic interactions of complex microbial ecosystems involved in agriculture, and climate change. However, poor correlations typically observed between RNA and protein expression datasets even for single organisms make it hard to infer microbial protein expression with any accuracy from metagenomic data, thus restricting movement beyond microbial catalogues and into functional analysis of microbial effector molecules. By contrast, mass spectrometry analysis of microbiome data at the protein level in theory allows direct measurement of dynamic changes in microbial protein composition, localisation and modification that may mediate host/pathogen interactions in complex microbial ecosystems, but analysis of such metaproteomic datasets remains challenging.
Here we describe a novel data analysis approach, MetaNovo, that searches complex datasets against the entire known protein universe, whilst still controlling false discovery rates, thus enabling metaproteomic data analyses without requiring prior expectation of likely sample composition or metagenomic data generation that classically inform construction of focussed, relatively small search libraries. MetaNovo directly identifies and quantifies the expressed metaproteomes, and estimates the microbial composition present in complex microbiome samples, using scalable de novo sequence tag matching and probabilistic optimization of very large, unbiased sequence databases prior to target-decoy search. We validated MetaNovo against the results obtained from the recently published MetaPro-IQ pipeline on 8 human mucosal-luminal interface samples, with comparable numbers of peptide and protein identifications being found when searching relatively small databases. We then showed that using an unbiased search of the entire release of UniProt (ca. 90 million protein sequences 1 ) MetaNovo was able to identify a similar bacterial taxonomic distribution compared to that found using a small, focused matched metagenome database, but now also simultaneously identified proteins present in the samples that are derived from other organisms missed by 16S or shotgun sequencing and by previous metaproteomic methods. Using MetaNovo to analyze a set of single-organism human neuroblastoma cell-line samples (SH-SY5Y) against
UniProt we achieved a comparable MS/MS identification rate during target-decoy search to using the UniProt human Reference proteome, with 22583 (85.99 %) of the total set of identified peptides shared in common. Taxonomic analysis of 612 peptides not found in the
Introduction
Characterizing complex mass-spectrometry data from clinical or environmental samples allows for potential insights into the complex metabolic pathways involved in processes as diverse as carbon sequestration and climate change to the susceptibility and progression of human diseases. Parallels have been drawn between the role of soil microbiota in the biosphere and the role played by gut microbiota in human health (Ochoa-Hueso, 2017). Soil microbes metabolize organic material derived from plants and store carbon in inert forms, while gut microbiota assist the human host in metabolizing complex dietary constituents, assisting with metabolism and detoxification (Blaser et al., 2016) . Microbial ecosystems play a wide-ranging role in the complex determinants of human well-being, with potential disease implications should the delicate balance be disrupted.
Genome and transcriptome sequencing approaches to microbiome analysis allow for functional and taxonomic characterization of the genes and organisms involved in complex microbial communities, but evidence for gene transcription does not in general correlate well with measured protein abundance (Castellana and Bafna, 2010) . On the other hand, metaproteomic and clinical proteomic approaches in principle allow researchers to obtain a snapshot of all the proteins present in a complex microbiome sample at a given time, providing a quantitative window into key functional components of complex pathways and organism interactions, including the direct measurement of dynamic changes in microbial protein composition, localisation and modification that may mediate host/pathogen interactions in the context of human health and disease.
Classically, the identification of peptides (and by inference, the parent proteins) from complex mass spectrometry datasets has been dependent on the availability of focussed, representative and relatively small sequence databases or spectral libraries against which to search tandem mass spectra; as a result, the field of proteomics has been primarily directed to the analysis of single organism proteomes to date. However, analysis of complex, multispecies samples -such as human microbiome samples, where the total number of microbial genes may vastly exceed the number of human genes -is far less straightforward for a variety of reasons, including: the vast majority of specific organisms in any given microbiome are likely to not have been cultured, identified, or characterised in the laboratory, so appropriate reference genomes may not exist to underpin proteomic data analyses; and the fact that massive expansion of proteomic sequence databases used in target-decoy-based peptidespectrum matching has been shown to lead to dramatically reduced identification rates due to reduced sensitivity and false discovery mis-estimation problems (Heyer et al., 2017; Blackburn & Martens, 2016) .
Previous methods for metaproteomic analysis have addressed these issues essentially by relying on prior expectation of the microbial composition of a given microbiome sample, for example using 16S sequencing data to produce a focussed metaproteome library to search.
However, the weaknesses in this approach are that: (i) it assumes that the 16S data itself provides a complete description of all bacteria present in the sample, which is probably not true; (ii) it assumes that appropriate reference bacterial proteomes exist and are close enough in sequence to the clinical isolate proteomes for proteomic data analysis to be valid, which may also not be true; & (iii) it automatically ignores all non-bacterial components of the microbiome. Furthermore, identified peptides may belong to multiple homologous proteins, complicating protein inference and quantification. Particular challenges faced by adult gut metaproteomics include inter-subject variability (Li et al, 2011) , combined with the need to factor in the influence of a very diverse and variable human diet. Thus, whilst matched metagenome bacterial sequencing is the current gold standard to create sequence databases to search metaproteomic mass spectrometry data against, such data is not always available nor necessarily complete. Moreover, such curated databases for a given microbiome typically do not include viral, fungal, host or other eukaryote proteomes that may be present, nor do they account for possible sequence polymorphisms compared to reference strains. The ideal database for mass spectrometry-based peptide identification in metaproteomic datasets would therefore be comprehensive, whilst excluding proteins that are genuinely absent, and would not be reliant on prior expectation of possible sample composition, nor would it require prior generation of DNA/RNA sequencing data to inform construction of a search database. (2016) showed that an iterative search of the human gut microbial integrated gene catalogue (IGC) produces comparable results to using a matched metagenome database.
De novo sequencing of peptides from mass spectrometry data has long been used for database filtration, allowing for rapid searches of very large search spaces with sequence tags prior to peptide-spectral matching (Frank et al, 2007) . Particularly considering significant intersubject variation and the polymorphism of clinical strains, de novo sequencing has been suggested as a viable strategy for peptide identification in gut metaproteomics (Blackburn & Martens, 2016) . However, scalable and robust de novo sequencing-based pipelines need to be able to process the rapidly expanding amount of proteomics and genomics information available.
Here we present a novel metaproteomic analysis pipeline -MetaNovo -based on mapping de novo sequence tags to very large protein sequence databases using a high performance and parallelized computing pipeline, generating compact databases for target-decoy analysis and protein posterior probability, and a minimal set of ranked proteins obtained such that each protein in the list contained at least one unique MS/MS scan ID relative to the set of proteins above its position in the list. The organism name was obtained from the UniProt FASTA headers, and summed NSAF values aggregated by organism in the minimal set and divided by the total to obtain an organism level posterior probability. Following this, the proteins in the unfiltered set were annotated with their respective calculated organism posterior probability. The unfiltered set of proteins was re-ranked based on the joint probability of the organism and protein probability values, which allows low abundance proteins with a high estimated relative abundance at the organism level to be favoured compared to proteins where both the protein and organism abundance was estimated to be low. Following the second ranking step, the database was re-filtered to obtain a minimal subset of proteins that could explain all mapped de novo sequence tags, based on estimated relative protein and organism abundance.
The pipeline can be obtained from GitHub or downloaded as a standalone Singularitycompatible Docker container from the Docker Hub. 6 The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD014214.
Mucosal-luminal interface samples
Mucosal-luminal interface (MLI) sample metagenomic and proteomics data.
Metagenome and proteomics data of 8 MLI samples from adolescent volunteers obtained during colonoscopy were downloaded from PRIDE 7 and through author correspondence. The sample processing, mass spectrometry and metagenomics database creation methods have already been described (Zhang et. al, 2016) .
MetaNovo database generation. The August 2017 release of UniProt 8 , containing ca. 90 million protein entries, was used to create a database containing 67246 entries. The default MetaNovo settings described above were used.
Database search using MaxQuant. MaxQuant version 1.5. Peptides were desalted in a 1ml C18 Supelco SPE cartridge. Samples were run on a Dionex with a 2cm 100μm trap column and a 40cm 75μm analytical column. Sample loading was normalised to an average total ion chromatogram (TIC) peak height of 1×1010. Peptides were separated by a 120 minute gradient from 5%B to 25%B, and Nano ESI set to 2.1kV for analysis on a Q-Exactive Orbitrap mass spectrometer (QE). The QE was operated in full ms1
to data dependent ms2 mode, and peptides were fragmented with a normalised collision energy of 25 and scanned with a resolution of 17 500. 
Bioinformatic analysis
Posterior error probability (PEP) score analysis. The PEP scores of peptides identified using MaxQuant were obtained from the peptides.txt output files. Significant differences between groups of interest were tested for using the Kruskal-Wallis non-parametric analysis of variance test followed by Dunn's post-hoc test using a custom python script. PEP score distributions were visualized using the python matplotlib library.
Taxonomic analysis. Peptide sequences were assigned to a lowest common ancestor using the UniPept pept2lca tool. Peptide and spectral counts were aggregated at selected phylum levels reported in the pept2lca output, with custom visualizations done using the Python matplotlib module. For the differential abundance analysis of the adult stool samples, intensity-based quantification was performed using normalized ion intensities, aggregated at selected phylum levels in each sample.
Pathway and gene set analysis of adult stool data. Table 2) . 9 An attempt to run the MetaPro-IQ pipeline against the UniProt database was not successful due to wall-time restrictions on a high performance cluster causing X!Tandem runs to fail. Posterior error probability scores. The PEP scores of human, contaminant, reverse and non-human peptides were compared using Kruskal-Wallis analysis of variance test followed by Dunn's test post-hoc analysis. A significant difference was found between groups (p-value 5.23e-58). Post-hoc, a significant difference (p-value 4.076e-49) was found between human and non-human peptides with as well as between non-human peptides and reverse hits -an indication that the proportion of false positives in the non-human peptide set is higher than human peptides, but still contains true positive identifications. See Supplementary Table 9 .
Perturbed KEGG pathways. 6 KEGG terms were differentially perturbed based on R gage analysis of ion intensity of the constituent proteins identified using InterProScan (q-value < 0.05). gage uses log fold changes as "per-gene" statistics, and is based on a parametric gene 
Conclusion
MetaNovo makes characterizing complex mass spectrometry data with an extremely large, scalable, unbiased search space feasible, allowing for novel peptide and polymorphism identification, even when genomic information is not available, and improving the accuracy and affordability of current clinical proteomic and metaproteomic analysis methods by leveraging the rapidly growing number of available sequences from genome and metagenome sequencing efforts. By tailoring a database for the samples to be analyzed in unbiased manner, MetaNovo allow proteomic identification to be carried out, unlimited by prior expectation. We have shown that using MetaNovo a sensitive characterization of the gut metaproteome allows for a simultaneous snapshot of the metabolic processes at play in both the host and the microbiome. Finally, the ability to search an extremely large database such
as UniProt provides the potential to identify pathogens and biomarkers that may be missed Peptide-rich eluate obtained for either FASP or in-solution tryptic digests was desalted using a homemade stage tip containing Empore Octadecyl C18 solid-phase extraction disk (Supelco). Activation, equilibration and peptide wash and elution were all carried out using centrifugation at 5000 g for 5 min. Activation and equilibration of the C18 disk was carried out using three rinses with 80% acetonitrile (ACN), followed by three rinses with 2% ACN, respectively. Peptide-rich solution was loaded onto the disk and centrifuged. Desalting was carried out using three washes of 2% ACN, followed by three washes of 2% ACN containing 0.1% formic acid (Sigma). Elution of desalted peptides into glass capillary tubes was carried out using three rounds of 100 Peptide fragmentation was performed via higher-energy collision dissociation (HCD) with the energy set at 25 NCE. Intensity threshold for ions selection was set at 1.7 e4 with charge exclusion of z = 1 and z > 5. The MS/MS spectra were acquired at a resolution of 17 500, with a target value of 2 × 105 ions or a maximum integration time of 120 ms and the isolation window was set at 4.0 m/z.
